Market Overview

Isogenica Licenses CIS Display Technology to Aro Biotherapeutics for Centyrin-based Biopharmaceutical Development

Share:

Isogenica Ltd today announced that it has signed a new licensing
agreement with Aro Biotherapeutics Company (Aro) of Philadelphia. USA,
that will leverage each other's strengths in recombinant protein
technologies and biopharmaceutical development. Isogenica is a leader in
the design and construction of highly diverse synthetic antibody
libraries and the use of novel in vitro polypeptide display systems. Aro
is focused on discovery and development of Centyrins, a protein drug
platform designed to uniquely address unmet needs through targeted
delivery of a variety of drug payloads to specific cells or tissues.

Isogenica has granted a licence to Aro to utilise its proprietary in
vitro CIS Display technology, for the discovery, development and
commercialisation of therapeutic products derived from Centyrin
libraries generated using this technology.

Aro will use the Isogenica technology to advance its internally
developed Centyrin drug pipeline.

Under the terms of the agreement, Isogenica will receive an upfront fee
and annual licence payments. If therapeutic products are advanced into
development, Isogenica is entitled to additional milestone payments. As
part of the agreement, Isogenica will undertake Centyrin discovery
services at its site on targets nominated by Aro.

Adam Collier, Isogenica's Director of Commercial Development
commented:
"Isogenica continues to attract leading-edge partners,
giving them access to our novel CIS Display technology and supporting
them in advancing their own discovery programmes. Aro is an exciting new
company with a unique technology and we look forward to our partnership
with them."

ENDS

About Isogenica Ltd www.isogenica.com

Isogenica is a drug discovery platform-licensing company focusing on the
design and build of diverse, fully synthetic, antibody libraries for use
in biopharmaceutical discovery. Partners can access an advanced camelid
single-domain antibody library (llamdA™) and state-of-the-art, fully
synthetic and highly diverse human Fab antibody libraries (Alexandria™).
The company uses its proprietary Colibra™ library technology to ensure
that the libraries very accurately reflect its advanced designs.
Libraries can be screened in various formats, including phage and CIS
Display, a proprietary in vitro display technology which maintains the
high diversity of the llamdA™ libraries through the discovery process.
CIS Display is also available as a stand-alone polypeptide display
technology.

View Comments and Join the Discussion!